Apoptosis, or programmed cell death, is involved in many biological processes including embryogenesis, development of the immune system, elimination of virus-infected cells, and maintenance of tissue homeostasis.
The mouse monoclonal antibody HFE7A (m-HFE7A), raised against human Fas, binds to both human and mouse Fas. 7, 8) Administration of m-HFE7A to mice induces apoptosis in thymocytes. However, in mice, m-HFE7A shows no sign of the hepatotoxicity observed with the hamster antimurine Fas monoclonal antibody Jo2. 9) Moreover, administration of m-HFE7A to mice prevents the injury of the liver induced by Jo2. Therefore, m-HFE7A may provide a useful treatment for autoimmune diseases such as rheumatoid arthritis and fulminant hepatitis.
A major limitation in the use of murine antibodies for human therapy is the human anti-mouse antibody response, resulting in potentially harmful reactions and the rapid clearance of circulating antibody. 10, 11) To reduce the immunogenicity of murine antibodies for human therapy, chimeric antibodies were initially developed. 12) Chimeric antibodies consist of the mouse variable domains and the human constant domains. Even chimeric antibodies are still capable of eliciting a significant immune response. 13) An approach to overcome the limitation in the clinical use of murine antibodies is humanization of murine antibodies. 14) This technique involves transplantation of the murine residues in the complementarity-determining regions (CDRs), which are important for antigen binding, into a relevant human antibody. However, direct grafting of only the CDR residues has sometimes decreased the binding affinity. 15, 16) Therefore, in addition to the CDR residues, some murine residues at the key positions in the framework region must also be incorporated into the human framework to maintain the proper CDR conformation. For this process, information on the three-dimensional structure is essential to minimize the number of murine residues to be transferred and avoid the human antimouse antibody response.
In this report, we describe humanization of m-HFE7A by the CDR grafting method for the treatment of the human diseases. Five versions of humanized HFE7A (h-HFE7A) induced the same degree of apoptosis in WR19L12a cells as chimeric HFE7A (chi-HFE7A) does. To further probe the structural basis on antibody humanization, we selected one of five h-HFE7As, h-HFE7A-d, since the d version has the smallest number of residues transferred from m-HFE7A among five h-HFE7As and determined the crystal structure of the h-HFE7A-d antigen-binding fragment (Fab) by X-ray crystallography. We discuss the comparison of the humanized structure with the parent mouse structure previously determined, 17) concerning the CDR conformation, and the segmental shift and flexibility of the CDR-L1 loop. 
Humanization of the Mouse Anti-Fas

MATERIALS AND METHODS
Molecular Modeling of m-HFE7A
To determine mouse residues to be transferred to human antibody, the molecular model of the m-HFE7A variable domains was constructed by homology modeling with the programs AbM (Oxford Molecular Inc.) and QUANTA/CHARMM (Accelrys Inc.). The template models of the framework region (residues in the variable domains except the CDR residues) were the crystal structure of the human immunodeficiency virus type 1 neutralizing antibody 50.1 (Protein Data Bank (PDB) code, 1GGI) for the light (L) chain and that of HyHEL-5 (PDB code, 2HFL) for the heavy (H) chain, respectively, due to their highest sequence identity with m-HFE7A. The models of the CDR residues were constructed based on the Chotia's study 18, 19) and the cluster analysis.
20)
The model of the CDR-H3 residues was constructed by the combinations of the sequence homology search of PDB and energy minimization. 21) After integrating the CDR residues into the framework model, a complete molecular model of m-HFE7A was energy minimized to eliminate unfavorable atomic contacts. The stereochemical parameters were analyzed with the program PROCHECK, 22) and the interatomic contacts and solvent accessibility were analyzed by the inhouse developed tools.
cDNA or Genomic DNA Cloning of the Human IgG Land H-Chains The human IgG L-chain gene was amplified by the polymerase chain reaction method (PCR) with the primers 5Ј-CGAATTCTGCCTTGACTGATCAGAGTTTCC-TCA-3Ј and 5Ј-CTCTAGATGAGGTGAAAGATGAGCTG-GAGGA-3Ј using a human lymphoid cDNA library (Life Technologies Inc.) as a template. The resulting PCR product was subcloned into pCR3.1 (Invitrogen Co.) to form pHL15-27. The 5Ј DNA fragment, which encodes for the H-chain constant region 1 (C H 1) and intron I, was amplified by PCR with the primers 5Ј-GGAAGCTTCCGCGGTCA-CATGGCACCACCTCTCTTGCA-3Ј and 5Ј-CTCTGCAGA-GAGAAGATTGGGAGTTACTGGAATC-3Ј using human genomic DNA (Clontech Laboratories, Inc.) as a template. The resulting PCR product was subcloned into pHSG399 (Takara Shuzo Co.) to form pIG5Ј03. Similarly, the 3Ј DNA fragment, which encodes for hinge, intron II, C H 2, intron III and C H 3, were amplified with the primers 5Ј-TCTCTGCA-GAGCCCAAATCTTGTGACAAAACTCAC-3Ј and 5Ј-GG-GGAATTCGGGAGCGGGGCTTGCCGGCCGTCG-CACTCA-3Ј. The resulting PCR product was subcloned into pHSG399 to form pIG3Ј08.
Construction of the Humanized HFE7A Expression Vectors The DNA fragments encoding for the three versions of the h-HFE7A L-chain variable domain (V L ), 7AL-a, 7AL-b and 7AL-g ( Fig. 1) were amplified with the appropriate primers by the overlap extension PCR (OE-PCR) method 23) using pME-L, which contains the m-HFE7A Lchain cDNA, as a template. Similarly, the DNA fragment coding for the h-HFE7A L-chain constant domain (C L ) was amplified with the appropriate primers using pHL15-27 as a template. The final PCR products for the complete h-HFE7A L-chains were digested with EcoRI and HindIII, and cloned into the same site of pEE12.1 (Lonza Biologics) yielding p7AL-a, p7AL-b and p7AL-g. Next, the expression vectors for another versions of the HFE7A L-chains, 7AL-d and 7AL-z were constructed, where the corresponding h-HFE7A V L domain were amplified with the appropriate primers by the OE-PCR method using p7AL-d and p7AL-z as templates. The final PCR products were digested with EcoRI and HindIII, and cloned into the same site of pEE12.1 yielding p7AL-d and p7AL-z, respectively. The DNA fragments encoding for the h-HFE7A H-chain variable domain (V H ) (Fig. 1) were amplified with the appropriate primers by the OE-PCR method using pME-H, which contains the m-HFE7A H-chain gene, as a template. The final PCR product was digested with ApaI and HindIII, and inserted into the same site of pEE6.1 (Lonza Biologics) to form pBL7A27. The pBL7A27 was digested with ApaI and KpnI, and ligated with an ApaI-KpnI DNA fragment coding for C H 1 and intron I of the human IgG H-chain isolated from pIG5Ј03. The plasmid designated as pBL7AF184 was obtained. The DNA fragment coding for V H , C H 1 and intron I of the human IgG Hchain was isolated from pBL7AF184 by HindIII/PstI digestion, and recloned into the same site of pIG3Ј08. The DNA fragment coding for the entire h-HFE7A H-chain was generated by EcoRI/HindIII digestion and cloned into the same site of pBluescript II SK(ϩ) to form p7AHV. Next, another h-HFE7A H-chain expression vector of p7APDHV was constructed. The corresponding h-HFE7A V H domain was amplified with the appropriate primers by the OE-PCR method The CDR residues are in angle brackets. The italicized mouse framework residues were transferred to the acceptor 8E10 along with the CDR residues, while the other residues except residue 109-L are identical to the corresponding residues in the acceptor 8E10. Residue 109-L was replaced with Thr, which is the consensus residue of the human subgroup III at this position. In PDHV, residue 75-H was replaced with Thr, which is the consensus residue of the human subgroup I at this position. using p7AHV as a template. The final PCR product was digested with HindIII and SacI, and cloned into the same site of p7AHV yielding p7APDHV.
Construction of Chimeric HFE7A The DNA fragment encoding for the m-HFE7A VL domain was amplified with the appropriate primers by the OE-PCR method using pME-L as a template. Similarly, the DNA fragment coding for the h-HFE7A C L domain was amplified with the appropriate primers using pM42B, which contains the human IgG Lchain cDNA, as a template. The final PCR product was digested with EcoRI and HindIII, and cloned into the same site of pEE12.1 yielding pGChime7AL. The DNA fragment encoding for the m-HFE7A V H domain was amplified with the appropriate primers by PCR using pME-H, which contains the m-HFE7A H-chain gene, as a template. This fragment was cloned into the same site of p7AHV to form pGChime7AH.
Transient Expression in COS-1 Cells To obtain the high-level expression of h-HFE7A and chimeric HFE7A (chi-HFE7A) in COS-1 cells, human cytomegalovirus major immediate early (hCMV-MIE) promoters 24) of p7AL-a, p7AL-b, p7AL-g, p7AL-d, p7AL-z, p7AHV, p7APDHV, pGChime7AL, and pGChime7AH were replaced with an SRa promoter 25) generated by PCR using pME18S as a template. As a result, pSR7AL-a, pSR7AL-b, pSR7AL-g, pSR7AL-d, pSR7AL-z, pSR7AHV, pSR7APDHV, pSRGChime7AL, and pSRGChime7AH, respectively, were obtained. COS-1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). They were harvested and washed twice in phosphate buffer saline (PBS) and resuspended at 10 7 cells ml Ϫ1 in PBS. A cell suspension of 10 ml was added to uncut the L-and H-chain plasmids (10 mg of each DNA in 10 ml PBS). The combinations of L-and H-chain vectors for expression were described in Table 1 . The cells and DNA were then subjected to 2 pulses of 600 V at a capacitance of 50 mF by using the "GTE-1" electroporation equipment (Shimadzu Co.). After electroporation, cells were plated in 5 ml of DMEM supplemented with 10% FBS and the supernatants were harvested 72 h after transfection.
Determination of the Expression Rate of Humanized and Chimeric HFE7As
The amounts of h-HFE7A and chi-HFE7A in the supernatant were determined using a sandwich enzyme-linked immunosorbent assay (ELISA). Microtiter plate wells were coated overnight with 50 ml of 1 mg ml Ϫ1 solution of goat anti-human IgG polyclonal antibody (Fc specific, Cappel Labs) at 4°C. After this and all subsequent steps, washing was performed with PBS containing 0.05% (v/v) Tween-20 (PBS-T). The wells were incubated with 50 ml of the culture supernatant of COS-1 cells, in which h-HFE7A and chi-HFE7A were expressed and diluted to various concentrations, for 1 h at 37°C. h-HFE7A and chi-HFE7A were detected with 100 ml aliquots of 1 : 3000 dilution of alkaline-phosphatase-labeled goat anti-human IgG polyclonal antibody (Fc specific, Cappel Labs) in PBS-T. After incubation and subsequent washing, the quantities of bound conjugate were detected by incubating the wells with a 1 mg ml Ϫ1 solution of p-nitrophenyl phosphate in 0.1 M 2,2Ј amino-methyl-propanediol buffer for 30 min at room temperature and measuring the absorbance at 405 nm. Purified human IgG1 (BioPur AG) was utilized as a standard.
Binding Assay to Human Fas-AIC2 The binding activity of h-HFE7A to human Fas-AIC2, a fusion protein of the extracellular regions of Fas antigen and IL-3 receptor, 7) was determined by ELISA. Microtiter plate wells were coated overnight with human Fas-AIC2 expressed in the supernatant of COS-1 cells. After washing with PBS-T, the wells were incubated with 50 ml of the culture supernatant of COS-1 cells, in which h-HFE7A and chi-HFE7A were expressed and diluted to various concentrations, for 1 h at 37°C. After washing, h-HFE7A and chi-HFE7A were detected with 100 ml aliquots of 1 : 3000 dilution of alkaline-phosphatase-labeled goat anti-human IgG polyclonal antibody (Fc specific, Cappel Labs) in PBS-T. After washing, the quantities of bound conjugate were detected as same as above. chi-HFE7A was utilized as a standard.
Competition-Binding Assay between m-HFE7A and Human Fas-AIC2 The competition-binding activity of h-HFE7A between m-HFE7A and human Fas was determined by ELISA. Microtiter plate wells were coated overnight with human Fas-AIC2 expressed in the supernatant of COS-1 cells. After washing with PBS-T, the wells were incubated with a culture supernatant of COS-1 cells, in which h-HFE7A and chi-HFE7A were expressed and diluted to various concentrations, and alkaline-phosphatase-labeled m-HFE7A for 1 h at 37°C. After washing, the quantities of alkaline-phosphatase-labeled m-HFE7A, which were bound to Fas-AIC2, were detected using CDP-Star (Tropix, Inc.) as a substrate. chi-HFE7A was utilized as a standard.
Apoptosis Induction Assay against WR19L12a Cells The apoptosis inducing activity of h-HFE7A against WR19L12a cells was determined by the XTT assay method. 26) WR19L12a cells were maintained in RPMI1640 supplemented with 10% FBS. A cell suspension (2ϫ10 6 cells ml Ϫ1 ) of 50 ml was mixed with the same volume of the culture supernatant of COS-1 cells, and cultured for 1 h. After washing with PBS-T, 100 ml of goat anti-human IgG polyclonal antibody (Fc specific, Kirkegaard and Perry Laboratories) was added, and cultured for more than 12 h. The viable cells were counted by the XTT assay.
Preparation and Crystallization of h-HFE7A Fab The preparation and crystallization of the h-HFE7A-d Fab were performed as described previously. 27) Briefly, IgG purified with a Protein-G affinity column (Amersham Biosciences Inc.) was digested to the Fab by papain. The Fab was purified with gel filtration (Superdex-75, Amersham Biosciences Inc.) followed by anion-exchange column chromatography (Mono-Q, Amersham Biosciences Inc.). The buffer for the Fab was changed to 10 mM Tris-HCl (pH 7.4) by gel filtration. The pooled protein was concentrated to 15 mg ml Ϫ1 Table 1 . Transient Expression Levels of h-HFE7A in COS-1 Cell
The h-HFE7A levels in the supernatant of COS-1 cells were assayed 72 h after transfection.
with Centricon-10 (Millipore) and used in the crystallization. Micro crystals of the Fab were obtained by the hanging drop vapor-diffusion method at 22°C with several precipitant solutions containing polyethylene glycol (PEG) 4000 and PEG 8000 in Crystal Screen-1 and -2 (Hampton Research) based on the sparse-matrix method. 28) Then, an optimization screen was performed with the Additive Screens kit (Hampton Research). Crystals suitable for X-ray analysis were obtained from a drop containing 2 ml of protein solution, 2 ml of reservoir solution (15% PEG 4000, 0.1 M sodium acetate (pH 4.6)), and 0.5 ml of 30% methanol, equilibrated against 900 ml of reservoir solution. The crystals grew to a maximum dimension of 1.2ϫ0.05ϫ0.05 mm 3 in 2-3 weeks. Data Collection, Phase Determination, and Structure Refinement A data set to 2.8 Å resolution was collected from two crystals at room temperature using synchrotron radiation at the BL-6B station of the Photon Factory (Tsukuba, Japan) with the wavelength set to 1.00 Å. The crystals belong to the orthorhombic spacegroup P2 1 . Diffraction data were processed with the DENZO and SCALEPACK programs.
30) The final data set contained 11136 unique reflections after merging 61689 observations (average redundancyϭ5.5) and was 91.0% complete in the resolution range 50.0-2.8 Å with an R merge (I) of 0.078. The structure of the h-HFE7A-d Fab was determined by molecular replacement using the program X-PLOR. 31 ) As a search model for molecular replacement, the crystal structure of the m-HFE7A Fab (PDB code, 1IQW) was used. A set of search models with the elbow angles (the angle between the two pseudo 2-fold rotation axes of the variable and constant domains) from 134°to 174°with 10°i ntervals was created with X-PLOR. The rotation search, the Patterson-correlation coefficient refinement, 32) and the translation search were performed for each search model, using data from 15.0 to 4.0 Å resolution. After 50 cycles of rigidbody refinement of the correctly oriented and positioned model, the crystallographic R factor dropped to 0.394 using data from 6.0 to 3.5 Å resolution.
Further structure refinement was carried out using X-PLOR and manual rebuilding of the Fab model was performed with the program O.
33) The free R-factor 34) (9% of the data) was used to monitor and verify improvements during refinements of the model. For the first round, structure refinement by the simulated annealing method followed by positional and grouped temperature factor refinement between 8.0 and 2.8 Å resolution yielded an R-factor of 0.223 (free Rfactorϭ0.380). At this stage, the mouse residues in the variable domains were replaced with the humanized residues. The constant domains of m-HFE7A were also replaced with those of the anti-thyroid peroxidase antibody Tr1.9 (PDB code, 1VGE) since the antibody Tr1.9 is a human antibody (IgG1 k) and have the same amino acid sequence to that of h-HFE7A-d in the constant domains, and the crystal structure of the antibody Tr1.9 Fab fragment has been determined with high resolution data (2.0 Å resolution). A subsequent rigid body refinement dropped the free R-factor to 0.331. Although clear electron density was observed for the variable domains, the electron density for the constant domains was poor. Therefore, the crystallographic parameters of occupancy for all atoms in the constant domains were fixed to 0.5, which were determined as a guide of the free R-factor. Similar observations of the different mobility between the variable and constant domains have been reported before. 35, 36) After several rounds of positional and individual temperature factor refinement and model rebuilding, positive electron densities above 3s were assigned as water molecules and the assignments were confirmed by visual inspection. The data collection and refinement statistics are shown in Table 2 .
Structure Analysis Hydrogen bonds and van der Waals contacts were assigned with X-PLOR and analyzed by visual inspection using the program O. The cut-off distance for hydrogen bonds and salt bridges was 3.4 Å, and that for van der Waals contacts was 4.2 Å. Crystal contacts were determined with X-PLOR using an interatom cut-off distance of 4.0 Å. The root mean square (rms) calculations for the main-chain atoms (N, Ca, C, O) were carried out with X-PLOR in two different ways. For the one way, the superposition and the rms calculation were done using the same set of atoms. For the other way, the superposition was done using the mainchain atoms in all the framework residues followed by the rms calculation for subsets of the CDR residues. The amino acid numbering and the definition of the CDR residues in this paper are according to Kabat et al. 37) 
RESULTS AND DISCUSSION
Grafting of the Mouse CDR Residues to the Human Antibody 8E10 Framework
We designed the h-HFE7A antibodies based on the predicted model by homology modeling. First, we selected the framework region as an acceptor for the donor m-HFE7A CDR residues. Based on the sequence comparison among subgroups of the human and mouse variable domains, the L and H chain of m-HFE7A are about 80% identical with the consensus sequences of the subgroup kIV and I of human antibodies, respectively, although no such combination could not be found among the human antibodies. Therefore, the human antibody 8E10, whose L and H chains belong to subgroups kIII and I, respectively, was selected as the acceptor. When aligned as shown in Fig. 1 , the sequence identities between m-HFE7A and 8E10 exceed 70% in both L and H chains. Next, at the framework positions where the amino acid residues differ between m-HFE7A and 8E10, the mouse framework residues predicted to be critical to maintain the CDR conformations were grafted along with the mouse CDR residues. The visual inspection and the analysis of interatomic contacts of the m-HFE7A molecular model were used to identify the critical positions to maintain the CDR conformations. Since the positions 38, 66, 67, and 69 of the H chain were supposed to be involved in the CDR contacts and the position 71 of the H chain was a canonical-structure determining residue, the mouse framework residues were also grafted at these positions in the humanized H chain, HV (Fig. 1) . The careful observation of the interface between the L and H chains suggested that the loop positions from 43 to 45, and from 76 to 86 of the L chain might cause the perturbation to the spatial arrangement of the CDRs. Therefore, three versions of the humanized L chains (7AL-a, 7AL-b, 7AL-g) were constructed.
After the biochemical activities of the three humanized versions were confirmed, the second-stage humanization was carried out. To further reduce the number of the donor residues from the framework, the position 1 of the L chain, which was Asp in m-HFE7A, was replaced with the corresponding acceptor residue Glu in 7AL-d and 7AL-z, since this minor displacement was expected to be less effective on the CDR contacts. The positions 81 and 103 of 7AL-d and 7AL-z were also replaced with the more commonly observed residues in the subgroup kIII (consensus residues). Similarly, the positions 44 and 75 of HV were replaced with the consensus residues of the subgroup I in PDHV.
Transient Expression of h-HFE7A in COS-1 Cells The COS-1 cell transfection procedure is rapid and easily reproducible and generates analytical quantities of protein for biochemical characterization. Transfection for the transient expression was performed by co-transfection of an equal amount of the L-and H-chain expression vectors, in which genes were positioned under the control of the hCMV-MIE promoter, into COS-1 cells. The h-HFE7A levels in the supernatant of co-transfected COS-1 cells were quantified by ELISA. However, sufficient levels of h-HFE7A to be analyzed biochemically were not obtained (data not shown). The high-level expression was observed after each hCMV-MIE promoter was replaced with the SRa promoter. This enabled a detailed biochemical characterization for all h-HFE7As. The expression levels of the five versions of h-HFE7A were found to be different ( Table 1 ). The expression levels of h-HFE7A-g, -d, z were about ten times weaker than those of h-HFE7A-a and -b. A similar result was obtained when the transfection was performed using a plasmid containing Lchain cDNA and H-chain genes of h-HFE7A on a same plasmid (data not shown). This result shows that the transient expression levels of h-HFE7A depend on some amino acid residues in the framework regions.
Analysis of h-HFE7A Expressed in COS-1 Cells Each h-HFE7A L-chain was co-expressed with the h-HFE7A Hchain in COS-1 cells. The resulting antibodies were analyzed by ELISA for their antigen-binding affinity (Fig. 2) . The results show that all versions of h-HFE7A bound to human Fas-AIC2 as well as the chimeric version. Next, five versions of h-HFE7A were tested for their competition-binding activity between m-HFE7A and human Fas by ELISA (Fig. 3) .
The results show that the five versions of h-HFE7A have the same degree of the competition-binding activity between m-HFE7A and human Fas as the chimeric version. The apoptosis inducing activity of h-HFE7A against WR19L12a cells was determined by the XTT assay method (Fig. 4) . The results show that the five versions of h-HFE7A have the same degree of apoptosis inducing activity against the WR19L12a cells as the chimeric version.
Crystal Structure Determination The crystal structure of the h-HFE7A-d Fab fragment was determined by molecular replacement and refined at 2.8 Å resolution to the crystallographic R-factor of 0.202 and the free R-value of 0.280 (Table 2, Fig. 5 ). The final model of the h-HFE7A Fab-d consists of the two chains, the L chain (residues 1-210) and the H chain (residues 1-226), and six water molecules. The coordinate error of the h-HFE7A-d model is 0.33 Å from a sA plot, 38) and 0.28 Å from a Luzatti plot. 39) Deviations from target-model geometry are 0.005 Å for bond length and 1.1°f or bond angles. Among all 433 residues, 79.8% are located in the most favorable regions of the Ramachandran plot analyzed by the program PROCHECK.
22)
Comparison of the h-HFE7A and m-HFE7A Variable Domains The comparison was performed between the h-HFE7A-d and m-HFE7A variable domains, which was previously determined by X-ray crystallography.
17) The h-HFE7A-d variable domains comprise the framework of the human antibody 8E10 with mouse residues replacing the six CDRs and additional mouse residues at positions 38, 66, 67, 69 and 71 of the H chain. In addition, residues at positions 81 and 103 of the L chain, and 44 and 75 of the H chain were replaced with human consensus residues, where 8E10 contains amino acid residues not commonly found in human antibodies (Fig. 1) . The results of the comparison for the main-chain conformations in the h-HFE7A-d and m-HFE7A variable domains are summarized in Table 3 . Despite sequence differences between the variable domains, the comparison revealed that the CDR residues have essentially the same conformation in both the Fab structures (Fig. 6) . The rms deviation for each CDR loop is in the range of 0.14-0.77 Å. The superposition for all the main-chain atoms in the variable domains yields an rms deviation of 0.71 Å. After superposition of all the framework residues, the respective rms deviations for the framework and CDR atoms are 0.74 and 0.60 Å, which indicates that the differences of the main-chain conformation between the framework residues and between the CDR residues are similar. Taking the variable domains separately, the rms deviation is 0.66 Å for the V L domain, and 0.63 Å for the V H domain. Thus, the association pattern of the V L and V H domains is maintained. Domain association differences can also be quantified from rotation and translation required for superposing the m-HFE7A and h-HFE7A-d V H domains after superposition of the V L domains. The rotation difference is 2.7°and the translation shift is 0.54 Å, which is quite small compared with those previously reported (3.7-8.9°/0.03-1.05 Å). 40, 41) Furthermore, all of the 26 hydrogen bonds between the CDR and framework residues in m-HFE7A were also observed in h-HFE7A-d. Of these, nine interactions occur using the side-chain atoms, which have similar sidechain conformations in both the Fabs.
Interaction between the CDR and Framework Residues Among the 168 residues in the h-HFE7A-d framework region, five residues (Lys38, Lys66, Ala67, Leu69 and Val71 of the H chain) are transferred from m-HFE7A. All of these five residues have essentially identical side-chain conformation and interact with the CDR-H2 residues in the same manner in both the Fab crystals.
The amino acid sequence of h-HFE7A-d is different from that of m-HFE7A at 32 positions in the framework region. Among the framework residues that interact with the CDR residues, position 1 of the L chain and position 48 of the H chain have different amino acid sequences (Asp1-L and Ile48-H in m-HFE7A, Glu1-H and Met48-H in h-HFE7A-d).
The difference of amino acid residues at these two positions gives no significant effect on the CDR conformation. It is difficult to estimate the contribution of residues at 1-L to the CDR conformation since both the mouse and humanized residues at 1-L are solvent-exposed and the mouse residue Asp1-L interacts with a residue from another molecule in the crystal. However, we believe that the side-chain atoms at 1-L give no significant contribution to the CDR conformation in both m-HFE7A and h-HFE7A-d.
In contrast to position 1-L, both the residues at 48-H are located inside the protein and interact with Phe63-H in CDR-H2. The side-chain conformations, typically the c-1 and c-2 angles, are very close to each other (Fig. 7) . Thus, only minor conformational rearrangement occurs around residue 48-H of h-HFE7A-d and the rearrangement gives no significant alteration to the CDR-H2 conformation. Phe63-H is located far from the expected antigen-binding site and inside the protein. We conclude that the difference of the amino acid residue at 48-H gives no critical influence on the CDR-H2 conformation and antigen binding.
Flexibility of the CDR-L1 Loop
Comparing the six CDR regions in h-HFE7A-d with those in m-HFE7A, the long CDR-L1 region (15 residues: residues 24-34) yields the largest rms deviation of 1.14 Å after superposition of the framework residues. However, the difference occurs mostly in the hairpin region of CDR-L1, which undergoes a segmental shift (Fig. 8) . After superposition of the framework residues, an rms deviation of the base part (9 residues: residues 24-27b and 32-34) is 0.59 Å, which is a similar value to those of the other CDRs, whereas the hairpin part (residues 27c-31, 6 residues) shows an rms deviation of 1.64 Å. Rms deviations after superposition using each part separately are 0.26 Å for the base and 0.39 Å for the hairpin part, indicating that no significant overall conformational change occurs in each part.
The segmental shift of CDR-L1 is most likely to be dependent on its flexibility rather than the crystal contacts, even 1542 Vol. 25, No. 12 a) Region refers to the residues that are used in the rms calculations. b) Superposition refers to the residues used to superimpose, from which the rms deviations were calculated. c) Rmsd refers to root-mean-square deviations. d) All refers to the backbone atoms in the variable domains (1-L-105-L, 1-H-113-H). e) Framework refers to the residues in the framework region. though residues 27, 27d and 28 in the m-HFE7A CDR-L1 and residues 27c, 27d and 32 in the h-HFE7A-d CDR-L1 have intermolecular interactions in the crystal. Analysis of the crystal packing shows that 18 residues in CDR-L2, -L3, -H1, -H2, and -H3 from h-HFE7A-d and six residues in CDR-L2, -H1 and -H2 from m-HFE7A are also involved in crystal contacts. However, all CDRs except CDR-L1 have low rms deviation values and retain nearly identical mainchain conformations under different crystal conditions and with different crystal contacts. Thus, the five CDR conformations are unaffected by the crystal packing. Furthermore, the average B-values over the main-chain atoms in both the CDR-L1 residues are relatively high (Fig. 9 ), indicating that both the loops are flexible. The differences in the B-values of the CDR-L3 and -H3 residues from m-HFE7A and h-HFE7A-d are presumably due to the crystal packing. Although both CDR-L3 and -H3 from m-HFE7A are not involved in the crystal contacts, those from h-HFE7A-d are involved, resulting in the relatively low B-values of the h-HFE7A-d CDR-L3 and -H3 residues. We conclude that the segmental shift of the CDR-L1 hairpin loop is caused mostly by its flexibility, and that the flexibility of CDR-L1 is affected by the crystal packing. Our results suggest that the CDR-L1 flexibility in m-HFE7A is maintained during humanization. In order to further elucidate a detailed structural mechanism on antibody humanization, it is necessary to compare both the antibodies in the complex form with the antigen.
Holmes et al. compared the variable domains of the mouse and humanized antibodies in the free state and those of the complex form with the antigen. 42, 43) In their studies, a number of small conformational differences were observed between the CDR residues from the mouse and humanized antibodies in the free state. However, the antigen-contacting residues of the mouse and humanized antibodies have identical conformations in the complex form. Furthermore, the side chain conformations are also nearly identical in the complexed structures. Although the conformation of the CDR-L1 loops from m-HFE7A and h-HFE7A-d shows the small differences in the free state, it is possible that one or both CDR-L1 undergo a conformational change and result in an identical conformation in the complexed structures.
In summary, we performed humanization of the m-HFE7A antibody for the treatment of the human diseases. All versions of h-HFE7A have the same binding affinity and competition-binding activity against the antigen as the chimeric version. The h-HFE7As also induce apoptosis as the chimeric version. Furthermore, the comparison of the threedimensional structures of the h-HFE7A-d and m-HFE7A Fabs indicated that the main-chain conformations of the CDR residues as well as the flexibility of the CDR-L1 loop are maintained during the humanization process. The hHFE7As are expected to be less immunogenic and currently under development for human therapy. Vol. 25, No. 12 
